MARKET

EGRX

EGRX

Eagle Pharmaceut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.17
+1.17
+2.66%
After Hours: 45.17 0 0.00% 16:11 05/16 EDT
OPEN
43.72
PREV CLOSE
44.00
HIGH
46.30
LOW
43.72
VOLUME
125.64K
TURNOVER
0
52 WEEK HIGH
58.25
52 WEEK LOW
36.48
MARKET CAP
573.59M
P/E (TTM)
16.27
1D
5D
1M
3M
1Y
5Y
Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 12:25
Eagle Pharmaceuticals Non-GAAP EPS of $3.41 misses by $0.25, revenue of $115.9M misses by $7.53M
Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q1 Non-GAAP EPS of $3.41 misses by $0.25. Revenue of $115.9M (+181.0% Y/Y) misses by $7.53M.
Seekingalpha · 05/09 10:52
Eagle Pharmaceuticals Q1 EPS $4.04 Beats $3.88 Estimate, Sales $115.90M Miss $123.33M Estimate
Eagle Pharmaceuticals (NASDAQ:EGRX) reported quarterly earnings of $4.04 per share which beat the analyst consensus estimate of $3.88 by 4.12 percent. This is a 1583.33 percent increase over earnings of $0.24 per share
Benzinga · 05/09 10:51
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
Eagle Pharmaceuticals' Q1 Adjusted Earnings, Revenue Soar
MT Newswires · 05/09 07:12
-- Earnings Flash (EGRX) EAGLE PHARMACEUTICALS Reports Q1 EPS $4.04, vs. Street Est of $3.66
MT Newswires · 05/09 06:54
Notable earnings before Monday's open
ACM,ADAP,APRN,AUD,AVDL,AZUL,BLDP,BNTX,BTAI,COTY,DTIL,DUK,EGRX,ELAN,ENR,FOLD,GSL,HEP,HGV,JLL,KNDI,KOS,LINC,MAC,MDGL,MRSN,MSGE,MTBC,OSG,PLTR,PRTY,RCM,RIDE,SPTN,TGNA,THS,TSN,VRTV,VTRS,WOW,WTRG For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 05/06 13:56
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Zacks · 05/04 15:07
More
No Data
Learn about the latest financial forecast of EGRX. Analyze the recent business situations of Eagle Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
0.00%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EGRX stock price target is 48.50 with a high estimate of 50.00 and a low estimate of 47.00.
High50.00
Average48.50
Low47.00
Current 45.17
EPS
Actual
Estimate
1.012.023.034.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 255
Institutional Holdings: 15.21M
% Owned: 119.76%
Shares Outstanding: 12.70M
TypeInstitutionsShares
Increased
47
320.63K
New
22
420.18K
Decreased
67
791.73K
Sold Out
10
514.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.21%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Michael Graves
President/Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer
Brian Cahill
Chief Operating Officer
Michael Moran
Executive Vice President
David Pernock
Independent Director
Luciana Borio
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
No Data
No Data
About EGRX
Eagle Pharmaceuticals, Inc. is an integrated pharmaceutical company. The Company takes a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. The Company identifies challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas, as well as in oncology. The Company offers three products: Ryanodex, dantrolene sodium) (Ryanodex), bendamustine ready-to-dilute (RTD) 500ml solution (Belrapzo), and rapidly infused bendamustine RTD (Bendeka). The Company market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. (Teva) markets Bendeka a lyophilized powder formulation of bendamustine hydrochloride in Japan.

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.